Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma
Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.
Oral paclitaxel shows similar efficacy to IV paclitaxel in phase II metastatic breast cancer trial
Can an oral pill match the power of standard IV chemo for advanced breast cancer?
A phase II randomized trial of 72 patients with HER2-negative recurrent or metastatic breast cancer found oral paclitaxel (DHP107) had an ob…
An oral breast cancer pill matched IV chemo in stopping tumor growth while sparing patients from nerve damage and hair loss.
Losartan reduces incidence and delays onset of paclitaxel-induced peripheral neuropathy in women with early-stage breast cancer
Losartan may reduce nerve pain from breast cancer chemotherapy in small trial
This single-center, open-label randomized controlled trial enrolled 89 women with early-stage breast cancer scheduled for weekly paclitaxel.
A common blood pressure drug called losartan significantly reduced nerve pain and improved quality of life for women receiving breast cancer…
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery.
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …